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Abstract
Background: Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down disease progression
of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung disease. Rapamycin, an inhibitor of fibroblast
proliferation could be a potential anti-fibrotic drug to improve the effects of pirfenidone.
Methods: Primary lung fibroblasts from IPF patients and human alveolar epithelial cells (A549) were treated in vitro
with pirfenidone and rapamycin in the presence or absence of transforming growth factor β1 (TGF−β). Extracellular
matrix protein and gene expression of markers involved in lung fibrosis (tenascin-c, fibronectin, collagen I [COL1A1],
collagen III [COL3A1] and α-smooth muscle actin [α-SMA]) were analyzed. A cell migration assay in pirfenidone, rapamycin
and TGF−β-containing media was performed.
Results: Gene and protein expression of tenascin-c and fibronectin of fibrotic fibroblasts were reduced by pirfenidone or
rapamycin treatment. Pirfenidone-rapamycin treatment did not revert the epithelial to mesenchymal transition pathway
activated by TGF−β. However, the drug combination significantly abrogated fibroblast to myofibroblast transition. The
inhibitory effect of pirfenidone on fibroblast migration in the scratch-wound assay was potentiated by rapamycin
combination.
Conclusions: These findings indicate that the combination of pirfenidone and rapamycin widen the inhibition range of
fibrogenic markers and prevents fibroblast migration. These results would open a new line of research for an anti-fibrotic
combination therapeutic approach.
Keywords: Pirfenidone, Rapamycin, Idiopathic pulmonary fibrosis, Pulmonary fibrosis, Cell migration, Extracellular matrix
proteins, Epithelial-mesenchymal transition
Background
Idiopathic pulmonary fibrosis (IPF) is the most common
and deadly form of idiopathic interstitial pneumonia.
The mortality from diagnosis is estimated between 3 and
5 years, and onset of the disease usually occurs in elderly
adults [1]. The pathogenic mechanisms are still unclear;
however, recent studies agree that the disease is the re-
sult of abnormal wound healing in response to micro-
injuries of the alveolar epithelium. The activated alveolar
epithelial cells cause the migration, proliferation, and ac-
tivation of mesenchymal cells with the formation of
myofibroblast foci [2]. The myofibroblasts secrete exces-
sive amounts of extracellular matrix (ECM) proteins, in-
cluding tenascin-c, fibronectin and collagens, with the
subsequent distortion of lung homoeostasis and archi-
tecture [1, 3]. These changes in the ECM composition
besides an increase in cytokines and growth factors, such
as transforming growth factor (TGF)−β, contribute to
IPF progression [2].
Over the past decade, growing evidence has demon-
strated the clinical benefits of anti-fibrotic treatment in
IPF, and two anti-fibrotic drugs are now recommended
in patients in the mild-moderate stage of the disease [4].
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In particular, pirfenidone (5-methyl-1-phenyl-2-[1H]-pyri-
done) has been shown to slow down the decline in FVC.
[5, 6]. Pirfenidone is a pleiotropic molecule that inhibits
TGF−β, collagen synthesis, and fibroblast proliferation,
and mediates tissue repair [7–12]. The anti-fibrotic activ-
ity and safety of this novel agent has been established in
lung, liver and kidney tissue [13]. Several molecular mech-
anisms responsible for the anti-fibrotic action of pirfeni-
done are still under study. The current clinical objective
in IPF treatment is to inhibit disease progression with
anti-fibrotic therapy [14], and the current research object-
ive is to find an anti-fibrotic capable of completely halting
or abrogate fibrosis. In this context, the in vitro anti-
fibrotic effect of drug combinations, together with the
safety profile of this therapeutic approach, should be ex-
plored in future clinical trials.
Rapamycin, an inhibitor of mammalian target of rapa-
mycin (mTOR)-mediated and a potent anti-proliferative
drug, was initially introduced into clinical practice to pre-
vent transplant rejection and later to treat mTOR diseases
such as lymphangioleiomiomatosis (LAM) [15, 16]. Rapa-
mycin presents some metabolic and bioavailability differ-
ences with other analogs such as everolimus [17]. All the
rapalogs are structurally similar to rapamycin differing
mainly at a single position of the lactone ring (C-40) [17].
Although everolimus exhibits greater polarity than rapa-
mycin, the bioavailability is only slightly improved and is
still relatively low. There are differences in the half-life,
potentially affecting the optimal dosing schedules [17].
More recently, the potent anti-fibrogenic action of rapa-
mycin has been demonstrated in animal models of hepatic
[18], renal [19], and pulmonary fibrosis [20]. The anti-
fibrotic effects of rapamycin in human lung fibroblasts are
mediated by a decrease in collagen synthesis (COL1A1,
COL1A2, and COL3A1) [20, 21]. Thus, it has been sug-
gested as a new anti-fibrotic pathway to explore in pul-
monary fibrosis [22] and is being tested in clinical trials.
Currently, the efforts of the scientific community are
focused on the search for anti-fibrotic strategies that
stop the abnormal repair process that leads to fibrosis
and dysfunction of the lung tissue in order to avoid the
progression of this devastating disease. Within this
framework, it is essential to find novel agents or combi-
nations of anti-fibrotic therapies. In this study, we aim
to elucidate the role of pirfenidone and rapamycin as a
new therapeutic approach for the treatment of lung fi-
brosis by analyzing first their anti-fibrotic potential in
vitro as a primary step.
Methods
Isolation of human lung fibroblasts
Adult human lung fibroblasts were obtained from lung bi-
opsies of six different IPF patients who underwent surgical
biopsy for the diagnosis of the disease (histologically
confirmed usual interstitial pneumonia). The harvested
lung tissue samples were maintained in DMEM high Glu-
cose with L-Glutamine (Gibco Life Technologies) medium
with HEPES (Sigma-Aldrich, St Louis, MO, USA) and in-
sulin human transferrin and sodium selenite (ITS)
(Sigma-Aldrich) until processing. Then cut into small
pieces, and placed into 6 well plates (Nunc Thermo Scien-
tific, Waltham, MA, USA) with growth medium; DMEM
supplemented with 10% fetal bovine serum (FBS, Gibco
Life Technologies), penicillin (100 U/ml)/streptomycin
(100 μg/ml) solution (Gibco Life Technologies) and 25 μg/
ml amphotericin B (Sigma-Aldrich). Cells were cultured at
37 °C in a humidified atmosphere of 5% CO2. Spindle-like
primary fibroblasts started to grow separately from tissue
samples on day 2 to 3. Outgrowth of fibroblasts took 1 to
2 weeks. Tissue samples were then removed by aspiration,
and cells were allowed to reach confluence. Fibroblasts at
confluence were expanded by trypsinization and passaged
every 4 to 5 days at 1:4 ratio. Pulmonary fibroblasts were
identified by the typical spindle morphology and immuno-
histochemistry; vimentin and α-smooth muscle actin (α-
SMA) positive, and factor VIII and surfactant C-negative
staining. Cells between passage numbers 4 and 7 were
used in this study.
Cell line culture
Bronchial-alveolar epithelial human cells (A549) were pur-
chased from the American Type Culture Collection
(ATCC CRM-CCL-185, Manassas, VA, USA) and cultured
in F12 K (Gibco Life Technologies, Grand Island, NY,
USA) medium supplemented with 10% FBS (Gibco Life
Technologies) and penicillin (100 U/ml) / streptomycin
(100 μg/ml) solution (Gibco Life Technologies) according
to the manufacturer’s recommendations. Cells were main-
tained at 37 °C in a humidified 5% CO2 atmosphere.
Cell viability assay
Cell viability was evaluated using a commercial colori-
metric assay (Quick Cell Proliferation Assay Kit II. MBL,
International Corporation, Woburn, MA, USA) accord-
ing to the recommended protocol. Briefly, cells (5 × 104/
well) were cultured in a 96-well microtiter plate (Nunc
Thermo Scientific) and treated with pirfenidone (Hoff-
mann-La Roche) (1 mg/ml), and rapamycin (Sigma-Al-
drich) (1 μg/ml), and the combination of both agents in
the presence of TGF−β (5 ng/ml) in a final volume of
100 μl/well of 2% FBS culture medium in triplicates for
72 h. Then, 10 μl/well of WST reagent was added and
plates were incubated for 2 h at 37 °C in standard cul-
ture conditions. After shaking the plates for 1 min, the
absorbance was computed at a wavelength of 450 nm in
each well using a microplate reader (Thermo Scientific)
with 650 nm of reference wavelength. The amount of
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the dye generated by activity of dehydrogenase is directly
proportional to the number of living cells.
Cell culture stimulation
Human lung primary fibroblasts and A549 cell line were
cultured in 6 well plates (Nunc Thermo Scientific) in the
appropriated medium with 10% FBS; when cells reached
80% confluence the medium was changed at 2% FBS.
Cells were stimulated with activated TGF−β (5 ng/ml)
(R&D Systems Minneapolis, MN, USA), in the presence
of pirfenidone (1 mg/ml) and rapamycin (1 μg/ml) dur-
ing 72 h. Besides, we stimulated cells with a combination
of rapamycin and pirfenidone without TGF−β, rapamy-
cin with TGF-β, pirfenidone with TGF−β and rapamycin,
pirfenidone and TGF−β. After the incubation period,
cells and supernatants were collected, separated by cen-
trifugation and frozen for further analysis. Doses of pir-
fenidone and rapamycin were chosen based on previous
reported studies [7, 9, 23–27] and our results from the
cell viability assay.
Western blot assay
Cells were grown in 6-well plates (Nunc) and incubated
with TGF−β (5 ng/ml), pirfenidone (1 mg/ml) and rapa-
mycin (1 μg/ml) for 72 h at 37 °C. Cells were then lysed
in Radio-Immunoprecipitation Assay (RIPA) Buffer
(25 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.1% so-
dium deoxycholate SDS) containing 1:100 phenylmethyl-
sulfonyl fluoride and phosphatase inhibitors (Sigma-
Aldrich). The final protein concentrations were deter-
mined with a bicinchoninic acid (BCA) method (Thermo
Scientific) according to the manufacturer’s specifications.
Prepared samples were heated to 100 °C for 5 min; for
each sample the same amount of total protein (20–
30 μg) was added to a well of 4–15% mini-protean TGX
precast gels polyacrylamide gel (Bio-Rad Hercules, CA,
USA) and resolved by SDS-PAGE. The separated pro-
teins were transferred to a nitrocellulose membrane
(Bio-Rad). The membranes were blocked for 1 h in Tris-
buffered saline (10 mM Tris-HCl pH 7.5 and 0.15 M NaCl)
containing 0.1% (v/v) Tween 20 and 5% (w/v) bovine serum
albumin (BSA) (Sigma-Aldrich), and then probed at room
temperature (RT) for 1 h with primary antibodies against
human tenascin-C (diluted 1:500; Abcam, Cambridge, UK
#ab3970), human E-cadherin (diluted 1:2000, Abcam
#ab76055), human EDA-fibronectin (diluted 1:400, Abcam
#ab6328), human collagen I (diluted 1:200 Abcam
#ab88147), human collagen III (diluted 1:500 Abcam
#ab6310) human α-SMA (diluted 1:1000, Sigma #A5228),
human α-tubulin (diluted 1:5000, Sigma Aldrich # T6199),
human vinculin (diluted 1:5000, Abcam #ab129002) and
human β-actin (diluted 1:5000, Sigma #A1978). Immunore-
active bands were detected with IgG horseradish
peroxidase-conjugated secondary antibodies (anti-mouse
diluted 1:1000; and anti-rabbit diluted 1:1000) (Dako,
Glostrup, Denmark) and visualized by enhance chemilu-
minescence detection reagents ECL Western blotting kit
(Bio-Rad) according to the manufacturer’s instructions in a
luminescent image analyzer (LAS 3000 Fujifilm) and were
then scanned for densitometry analysis (Multi Gauge soft-
ware, Fujifilm). Results were expressed as a ratio of band
density to total β-actin, vinculin or α-tubulin.
RNA extraction and real-time polymerase chain reaction
(RT-PCR)
Total RNA was isolated from cultured cells, after treat-
ment with TGF−β, pirfenidone and rapamycin following
the same protocol explained above, using the Qiagen
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according
to the manufacturer’s recommendations. Samples were
digested with DNase I (Qiagen) to remove contaminat-
ing genomic DNA. RNA concentration and purity of
each sample were measured using UV spectrophotom-
etry. A total of 1 μg of RNA was reverse-transcribed
using the iScript cDNA synthesis kit (Bio Rad) with oligo
deoxythymidine and random hexamer primers. The re-
verse transcriptase reaction proceeded in a total volume
of 20 μl in a conventional thermal cycler (Bio-Rad) at
25 °C for 5 min, followed by 30 min at 42 °C and 5 min
at 85 °C. Reaction volumes of 20 μl were placed in 384-
well optical reaction plates with adhesive covers (ABI
Prism™ Applied Biosystems, Foster City, CA, USA) using
SYBR Green PCR Master Mix and specific sequence
primers (Sigma). Glyceraldehyde-3-phosphate dehydro-
genase (GADPH) mRNA amplified from the same sam-
ples served as the internal control. Samples were heated
to 95 °C for 10 min and then PCR amplification was
achieved by 40 cycles at 95 °C for 15 s and 60 °C for
1 min using the ABI Prism 7900 (Applied Biosystems).
The relative expression of each targeted gene was nor-
malized by subtracting the corresponding housekeeping
genes (β-actin, GADPH, HPRT and RNA18s) threshold
cycle (Ct) value using the comparative CT method
(ΔΔCt methods).
Cell migration assay
Cell migration was monitored from a confluent area to
an area that was mechanically denuded of cells (scratch-
wound assay). Cells were grown in 6-well plates (Nunc)
to a confluent monolayer and then serum-deprived for
24 h. After the medium was discarded, a scratch was
created in a straight line across the cells with a p20 pip-
ette tip. The plates were then rinsed with phosphate
buffered saline (PBS) to remove the suspended cells and
incubated with the specific media supplemented with
TGF−β (5 ng/ml), pirfenidone (1 mg/ml), rapamycin
(1 μg/ml) or the combination of the three agents.
Twenty-four and 72 h after the treatment, cells were
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monitored and photographed under a light microscope,
and the distance cover by the cells in the wound closure
was analyzed with Image J software (https://imagej.nih.
gov/ij/ National Institute of Health NIH, Bethesda, MD,
USA). Cells treated with drug-free medium were consid-
ered as controls.
Statistical analysis
All results are expressed as mean ± SEM of independent
experiments. Statistical analysis was performed in Graph
Pad Prism 5.01 (Graph Pad Software, San Diego, CA,
USA). Significance is indicated as follows: *p < 0.05,
**p < 0.01, ***p < 0.001. * indicates the comparison be-
tween samples treated with TGF−β and all the other
conditions: TGF−β versus untreated samples (control);
TGF−β versus rapamycin and pirfenidone (rapa/pirfe);
and samples treated with TGF−β in combination with
rapamycin (TGF−β/rapa); pirfenidone (TGF−β/pirfe) or
both (TGF−β/rapa/pirfe). #p < 0.05, ##p < 0.01, ###p < 0.
001. # indicates significant differences between control
versus samples treated with rapamycin and pirfenidone
in absence of TGF−β.
Results
Pirfenidone and rapamycin are well tolerated by human
lung fibroblasts and alveolar epithelial cells
Cell viability was assayed with the WST reagent in fibro-
blasts and A549 cells cultured in 96-well plates and
treated with TGF−β (5 ng/ml), pirfenidone (1 mg/ml)
and rapamycin (1 μg/ml) for 72 h. The cell toxicity assay
demonstrated that pirfenidone and rapamycin, in
addition to the combination of the 2 agents with TGF−β
(5 ng/ml), did not cause cellular death when compared
to untreated cells (control) and were well tolerated for
the treatment period of 72 h (Fig. 1). We then selected
the doses of 1 mg/ml for pirfenidone, in accordance with
the results obtained by other Groups [7, 9, 23–27], 1 μg/
ml rapamycin and 5 ng/ml of TGF−β to be used in the
following studies for a treatment period of 72 h.
Pirfenidone and rapamycin treatment inhibits ECM
protein expression in lung fibrotic fibroblasts
Fibroblasts were obtained from IPF patients submitted
to lung biopsies for the diagnosis of interstitial disease.
After the cultures were established, we stimulated the
cells with TGF−β (5 ng/ml), pirfenidone (1 mg/ml) and
rapamycin (1 μg/ml). Besides the treatment of rapamycin
and pirfenidone without TGF−β, rapamycin alone with
TGF−β, pirfenidone alone with TGF−β and the combin-
ation of rapamycin and pirfenidone with TGF−β for
72 h. Western blot and RT-PCR were performed to
analyze the protein and gene expression of the different
markers involved in the fibrotic process.
We observed a significant decrease in tenascin-c, and
collagen III when cells were incubated with pirfenidone
or rapamycin.
Tenascin-c
Previous studies conducted by our Group [28] and
others [29] have shown a clear induction of tenascin-c in
the fibrotic fibroblasts from IPF patients compared to
other interstitial diseases. We wanted to test the effect of
pirfenidone and rapamycin on tenascin-c in lung fibro-
blasts from IPF patients treated with the pro-fibrotic fac-
tor TGF−β. As shown in Fig. 2a, b, we found clear
inhibition of protein and gene expression levels when
cells were treated with both drugs. The response of the
treatment in the presence of TGF−β were clearer in both
the gene expression analysis and the protein level. How-
ever, the effect was likely mediated by rapamycin. Further-
more, the incubation with pirfenidone and rapamycin in
absence of TGF−β resulted in a significant decrease of
tenascin-c, as compared control cells with rapamycin-
pirfenidone treatment.
Fibronectin
Another component of the ECM that plays an important
role in the maintenance of lung homeostasis and wound
healing is fibronectin (FN). Due to its implication in the
development of pulmonary fibrosis and its pro-fibrotic
role in IPF, we analyzed the protein and gene expression
of FN in lung fibroblasts. As shown in Fig. 2c, we ob-
served a significant increase of protein level in TGF−β
stimulated fibroblasts when compared to the control.
However, we found a non-significant reduction in the
FN protein expression when cells were incubated with
pirfenidone and rapamycin. The gene expression of
Fig. 1 Effect of TGF−β, pirfenidone and rapamycin on the viability of
lung primary fibroblasts and A549 cells. Primary lung fibroblasts and
bronchial epithelial human cells (A549) were incubated with pirfenidone
(1 mg/ml) and rapamycin (1 μg/ml) in addition to the combination of
the two agents with TGF−β (5 ng/ml) for 72 h, viability was measured
with the WST reagent. No significant cytotoxic effect was observed for
any combinatory treatments. The bars represent the mean values ± SEM
of viability % related to control samples in three different experiments
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fibronectin induced by TGF−β was clearly inhibited by
the combination of pirfenidone and rapamycin, but the
effect might likely be due to the action of pirfenidone
(Fig. 2d). Moreover, when cells were stimulated with
rapamycin and pirfenidone in absence of TGF−β we ob-
served a slight increase of protein and gene expression
of fibronectin but this was not statistically significant.
Collagen type I and III
The overexpression of collagen in fibrotic lungs has been
shown to be a key factor in tissue dysfunction. Following
the same protocol, we analyzed the levels of collagen
type I (COL1A1) and collagen type III (COL3A1) in lung
fibroblasts when they were stimulated with TGF−β,
pirfenidone and rapamycin for 72 h. The combination of
pirfenidone and rapamycin with or without TGF−β did
not alter the high basal levels of COL1A1 protein ex-
pression in fibroblasts from IPF patients. This high level
of protein expression in control samples could due to
the fibroblasts´ origin from fibrotic lung areas. On the
other hand, levels of COL3A1 protein were inhibited by
the treatment of rapamycin and pirfenidone in the pres-
ence of TGF−β. Furthermore, the gene expression of
both collagen I and III after treatment with TGF−β
was abolished by pirfenidone or rapamycin, the most
definitive response to the combined treatment of pir-
fenidone and rapamycin after TGF−β was found in
collagen III (Fig. 3a, b, c, d).
a c
b d
Fig. 2 Pirfenidone and rapamycin effect in protein and gene expression of tenascin-c and fibronectin in human lung fibroblasts from IPF patients.
Primary lung fibroblasts from IPF patients were treated with TGF−β (5 ng/ml), pirfenidone (1 mg/ml) and rapamycin (1 μg/ml) for 72 h. a The total
cell lysates were subjected to immunoblot analysis for tenascin-c. The data shown are mean values ± SEM of four different experiments. b Results
of tenascin-c transcript fold changes expressed as relative gene expression (RGE) analyzed by RT-PCR. c Fibronectin protein level. Density of protein bands
were normalized against vinculin and are shown as ratios. d Fibronectin transcript fold changes expressed as relative gene expression (RGE). Charts
represent mean values ± SEM of four different experiments. Levels of significance: *p < 0.05; ** p < 0.01; ***p < 0.001. * indicates the comparison between
samples treated with TGF−β and all the other conditions: TGF−β versus untreated samples (control); rapamycin and pirfenidone (rapa/pirfe); and samples
treated with TGF−β in combination with rapamycin (TGF−β/rapa); pirfenidone (TGF−β/pirfe) or both (TGF−β/rapa/pirfe). #p < 0.05; ## p < 0.01. # indicates
the comparison between untreated cells (control) and samples treated with rapamycin and pirfenidone in the absence of TGF-β (rapa/pirfe). n.s statistically
not significant
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The fibroblast to myofibroblast transition is inhibited by
pirfenidone and rapamycin treatment combination
We studied the gene and protein expression of α-SMA
as an indicator for fibroblast transformation into fibrotic
active myofibroblasts. As expected, fibroblasts from fi-
brotic lungs showed a high protein expression of α-
SMA, and the treatment with TGF−β increased α-SMA
gene expression (Fig. 4a, b). This increase was signifi-
cantly reduced with the treatment of pirfenidone and
rapamycin, although pirfenidone alone had a clearer in-
hibitory effect. Interestingly, cells treated with both
drugs in the absence of TGF−β also showed a significant
decrease of α-SMA levels when compared to control
samples. These results suggest that the transformation
of fibroblasts to myofibroblasts in IPF fibroblasts is
inhibited by pirfenidone and rapamycin, but the effect
was mainly due to the action of pirfenidone.
Pirfenidone and rapamycin treatment prevent fibroblast
migration
We performed the scratch assay with primary lung fibro-
blasts from IPF patients. After the scar, cells were treated
with TGF−β (5 ng/ml), pirfenidone (1 mg/ml), rapamy-
cin (1 μg/ml) and the combination of all three agents for
24 and 72 h with the medium supplemented with 2%
and 10% of FBS, as explained above. The cell migration
assay, analyzed with Image J software, showed a de-
creased number of migrated cells after a scratch wound
a c
b d
Fig. 3 Collagen I and III gene expression are decreased by pirfenidone and rapamycin, while only the protein expression level of collagen III is
inhibited by pirfenidone and rapamycin. Primary lung fibroblasts from IPF patients were treated with TGF−β (5 ng/ml), pirfenidone (1 mg/ml) and
rapamycin (1 μg/ml) for 72 h. a Densitometric analysis expressed as mean ± SEM and a representative blot showing the unchanged effect in
COL1A1 levels by pirfenidone and rapamycin. b COL1A1 gene expression measured by RT-PCR was decreased by pirfenidone and rapamycin in
IPF fibroblasts. Bars represent mean ± SEM values of the transcript fold changes expressed by relative gene expression (RGE) of four different experiments.
c COL3A1 protein expression decreases with the combination treatment of rapamycin and pirfenidone. Bars expressed as mean ± SEM values. Treated
samples with rapamycin and pirfenidone in the absence of TGF−β show a significant decrease of the protein compare to controls. d COL3A1 gene
expression showing a significant decrease when cells were treated with rapamycin and pirfenidone combination treatment. Levels of
significance: *p < 0.05; ** p < 0.01; ***p < 0.001. * indicates the comparison between samples treated with TGF−β and all the other conditions:
TGF−β versus untreated samples (control); rapamycin and pirfenidone (rapa/pirfe); and samples treated with TGF−β in combination with rapamycin
(TGF−β/rapa); pirfenidone (TGF−β/pirfe) or both (TGF−β/rapa/pirfe). ### p < 0.001. # indicates the comparison between untreated cells (control) and
samples treated with rapamycin and pirfenidone (rapa/pirfe). n.s statistically not significant
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was made across the cells and treated with pirfenidone
and rapamycin or the combination of both agents when
compared with untreated cells or cells stimulated with
only TGF−β. In control and TGF−β treated samples,
fibroblasts filled the scratch as early as 24 h after the start
of incubation. In contrast, when cells were treated with
pirfenidone and rapamycin, the migration took up to 72 h.
The same protocol was repeated in a culture medium sup-
plemented with 2% (Fig. 5a) and 10% (Fig. 5b) FBS to en-
sure that the FBS was not interfering with the migration
process in control and treated cells. As shown in the
graph, the same motility pattern was observed with the
different concentrations of FBS assayed.
Pirfenidone and rapamycin inhibit the synthesis of pro-
fibrotic markers induced by TGF-β in alveolar epithelial
cells
In order to study the effect of pirfenidone and rapamy-
cin in lung epithelium, we conducted the same protocol
explained above for primary fibroblasts with A549 cells.
Culture cells were incubated with TGF−β (5 ng/ml), pir-
fenidone (1 mg/ml) and rapamycin (1 μg/ml) for 72 h,
and after the incubation period, cells were collected and
total RNA and protein were extracted.
Tenascin-c
The tenascin-c levels from A549 cells incubated with
TGF−β, pirfenidone and rapamycin for 72 h were ana-
lyzed western blot and RT-PCR. We found a significant
decrease of tenascin-c in cells incubated with pirfeni-
done and rapamycin in absence of TGF−β. However,
there was only a slight decrease of tenascin-c level in
cells treated with rapamycin after TGF−β, indicating the
role of this drug in inhibiting the protein expression of
this ECM protein. (Fig. 6a, b).
Fibronectin
We analyzed the protein expression of FN in A549 cells.
Western blot indicated that treatment with pirfenidone
and rapamycin decreased the induced FN protein levels
(Fig. 6c), and treatment with both drugs alone resulted
in a partial inhibition of FN. Moreover, when FN tran-
script was analyzed by RT-PCR, we found that pirfeni-
done and rapamycin combined treatment reduced the
increased levels induced by TGF−β, although the differ-
ence did not reach statistical significance (Fig. 6d), sup-
porting the results obtained in the protein expression
analysis.
Collagen type I and III
We also examined the effect of pirfenidone and rapamycin
treatment in the synthesis of collagen when alveolar epithe-
lial cells were stimulated with TGF−β. We observed an in-
crease of COL1A1 and COL3A1 protein with TGF−β that
was inhibited by the presence of pirfenidone and rapamycin,
but the addition of both drugs did result in a lower decrease
of only the collagen type III protein (Fig. 7a, c). We then
studied the gene expression of COL1A1 and COL3A1 in
a
b
Fig. 4 Fibroblast to myofibroblast transformation is inhibited by
pirfenidone and rapamycin treatment. α-SMA marker was studied in
primary lung fibroblasts from IPF patients treated with TGF−β (5 ng/
ml), pirfenidone (1 mg/ml) and rapamycin (1 μg/ml) for 72 h. a
Western blot analysis in cell lysates. Graphs represent means ± SEM
of target/control ratios obtained by densitometric analysis of each
experiment results. b The analysis of α-SMA gene expression after
72 h treatment showed differences between samples treated with
TGF−β in the absence or presence of pirfenidone and rapamycin.
α-SMA transcript fold changes expressed as relative gene expression
(RGE) measured by RT-PCR in fibroblasts from IPF patients, mean ±
SEM of four different experiments normalized using four different
housekeeping genes as control (β-actin, GADPH, HPRT, and RNA18s).
Levels of significance: ** p < 0.01; ***p < 0.001.* indicates the
comparison between samples treated with TGF−β and all the
other conditions: TGF−β versus untreated samples (control); rapamycin
and pirfenidone (rapa/pirfe); and samples treated with TGF−β in
combination with rapamycin (TGF−β/rapa); pirfenidone (TGF−β/pirfe)
or both (TGF−β/rapa/pirfe). #p < 0.05. # indicates the comparison
between untreated cells (control) and samples treated with rapamycin
and pirfenidone (rapa/pirfe). n.s statistically not significant
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a
b
Fig. 5 Pirfenidone and rapamycin inhibited the TGF−β-induced migration of human IPF lung fibroblasts. Cell migration assay were performed in
fibroblasts from IPF patients incubated with TGF−β (5 ng/ml), rapamycin (1 μg/ml) and pirfenidone (1 mg/ml). Images show that cell migration
occurred within 72 h from culture scratch in medium containing 2% (a) and 10% (b) fetal bovine serum (FBS) in the presence of TGF−β, combination of
TGF−β and rapamycin, TGF−β and pirfenidone, and the combination of TGF−β, rapamycin and pirfenidone. The uncovered area has been quantified by
the ImageJ Software at each time point and represented in the graphs as mean values ± SEM of three different experiments. Magnification, 100X. Levels
of significance; * indicates the statistical significance between all conditions assayed at 72 h time point. # indicates the significance between scratch and
24 and 72 h time points for each treatment conditions
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the same samples, and found that both genes increased their
expression with TGF−β after 72 h of treatment. Pirfenidone
and rapamycin combination significantly inhibited the colla-
gen type III transcript induced by TGF−β (Fig. 7b, d).
Pirfenidone and rapamycin treatment does not revert the
epithelial to mesenchymal transition (EMT) pathway
activated by TGF−β in A549 cells
To gain deeper insight into the role of the combination
pirfenidone and rapamycin treatment in the inhibition of
the EMT pathway activated by TGF−β, E-cadherin
marker was studied in A549 cells after 72 h of treatment
with TGF−β and both drugs.
E-cadherin
When the epithelial cell marker E-cadherin was ana-
lyzed, we observed that TGF−β inhibited the synthesis
of both protein and gene expression, indicating an acti-
vation of EMT in A549 cells. Treatment with pirfeni-
done and rapamycin alone did not significantly affect
the E-cadherin expression. However, the effect of these
drugs in combination with TGF−β failed to recover the
synthesis level of E-cadherin (Fig. 8a, b).
Discussion
Pirfenidone is currently one of the primary choices for





Fig. 6 Inhibitory effect of pirfenidone and rapamycin on tenascin-c and fibronectin gene and protein expression in bronchial epithelial human
cells. A549 cells were incubated with TGF−β (5 ng/ml), pirfenidone (1 mg/ml) and rapamycin (1 μg/ml). Protein and gene expression were determined
after the 72 h incubation period. a Representative immune blot showing the expression of tenascin-c in A549 cells. The bar chart summarizes the
densitometric analysis of total protein expression normalized to β-actin. b Analysis of tenascin-c gene expression normalized with four different
housekeeping genes (β-actin, GADPH, HPRT, and RNA18s). The bars represent the mean values ± SEM of the transcript fold changes
expressed as relative gene expression (RGE) in at least three different experiments. c Fibronectin protein expression measured in cell lysates by western
blot in at least three different experiments. The bar chart represents the densitometric analysis using α-tubulin as loading control. d Fibronectin gene
expression was normalized using four different housekeeping genes as control (β-actin, GADPH, HPRT, and RNA18s). Bars describe the mean values ±
SEM of the transcript fold changes, expressed as relative gene expression (RGE) between control and samples treated with TGF−β, pirfenidone and
rapamycin. Level of significance: *p < 0.05; ** p < 0.01. * indicates the comparison between samples treated with TGF−β and all the other conditions:
TGF−β versus untreated samples (control); rapamycin and pirfenidone (rapa/pirfe); and samples treated with TGF−β in combination with rapamycin
(TGF−β/rapa); pirfenidone (TGF−β/pirfe) or both (TGF−β/rapa/pirfe). n.s statistically not significant
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not stop or cure the disease completely, suggesting that
a combination with other compounds involved in differ-
ent pathways could be required in order to modify the
fatal outcome [14].
In this context, this study was designed to test the po-
tential role of the combination treatment of pirfenidone
with rapamycin to improve the anti-fibrotic in vitro ef-
fect. Our cytotoxic assay showed no statistically signifi-
cant changes in cell viability between control and treated
cells, suggesting that the used concentration of pirfeni-
done and rapamycin had no cytotoxic effect. Both drugs
have already been used separately, with different clinical
indications and satisfactory tolerance [14–16]. It has
been reported that pirfenidone exhibits an inhibitory
effect on a host of cell types in concentrations ranging
from 0.2 to 2.0 mg/ml with no cytotoxic effect in vitro
[24], and the drug is being administered orally at a daily
dose of 2403 mg with tolerable degree of adverse effects
in patients with pulmonary fibrosis [9]. Rapamycin,
meanwhile, is already being used in cancer, transplant
and LAM. An analog of rapamycin, everolimus, did not
demonstrate benefit for IPF in a previous study [30].
However, everolimus and rapamycin present a different
clinical profile in other diseases [31], and this indicates
that choosing the correct mTOR inhibitor should be
considered carefully. Rapamycin prevents and inhibits
progression of ongoing pulmonary fibrosis caused by ex-
pression of TGF−α and increased epidermal growth
a c
b d
Fig. 7 Pirfenidone and rapamycin combined treatment inhibit the expression of collagen type I and III induced by TGF−β in alveolar human
epithelial cells. A549 cells were incubated with TGF−β (5 ng/ml), pirfenidone (1 mg/ml) and rapamycin (1 μg/ml) for 72 h. a and c The expression
of COL1A1 and COL3A1 were measured by western blot. Representative immunoblot analysis of at least three different experiments normalized
by α-tubulin. The combination of rapamycin and pirfenidone treatment inhibits the protein expression of collagen type III. Gene expression b and
d were analyzed in A549 cells after the drug treatment by RT-PCR. Reported values are means ± SEM of the transcript fold changes expressed as
relative gene expression (RGE) normalized by four housekeeping genes and calculated on the level of untreated (control) cells. Only collagen type
III gene expression is decreased by the treatment of rapamycin and pirfenidone. Levels of significance; *p < 0.05; **p < 0.01 * indicates the comparison
between samples treated with TGF−β and all the other conditions: TGF−β versus untreated samples (control); rapamycin and pirfenidone (rapa/pirfe);
and samples treated with TGF−β in combination with rapamycin (TGF−β/rapa); pirfenidone (TGF−β/pirfe) or both (TGF−β/rapa/pirfe). n.s statistically
not significant
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factor receptor (EGFR) signaling [21]. Currently, rapa-
mycin is being evaluated in a clinical trial for IPF. Fur-
thermore, the mTOR pathway is a hallmark of aging,
and recent studies have shown it to be overexpressed in
the fibrotic lungs of patients with a more detrimental
progression [32].
Previous studies performed by our Group have shown
the importance of ECM protein expression in the fi-
brotic process that occurs in IPF lungs [28]. In this
study, we tested the combination of pirfenidone and
rapamycin treatment to abolish the synthesis of ECM
proteins. We incubated the cell cultures with pirfeni-
done and rapamycin in absence or presence of the pro-
fibrotic cytokine TGF−β. We observed different effects
of pirfenidone and rapamycin when we analyzed the ex-
pression of the main proteins involved in the fibrotic
process. We found that there is an inhibitory effect in
the synthesis and gene expression of the ECM proteins,
indicating that the treatment together is more efficient
that the use of a single drug. The results indicated that
rapamycin was able to inhibit the protein and gene ex-
pression of tenascin-c, and collagen I in fibroblasts and
epithelial cells treated with TGF−β. On the other hand,
pirfenidone succeeded in inhibiting the increase of fibro-
nectin and α-sma in primary lung fibroblasts. These ag-
gregated findings together demonstrated that each drug
acts in different pathways and the use of both com-
pounds would increase the anti-fibrotic range of action.
Therefore, the drug combination increased the anti-
fibrotic in vitro effect although a synergic effect was
minimally present. Further studies are needed to better
understand the role of each drug to inhibit the fibrotic
process. These findings reveal the importance for a com-
bined therapy that may result in a more efficient treat-
ment to inhibit the ECM over-expression in the fibrotic
process. The important role of both fibronectin and col-
lagen in regulating the homeostasis of extracellular
matrix and the inhibitory effect of pirfenidone in TGF−β
stimulated fibroblasts has been reported [33]. Although
pirfenidone has been shown to inhibit the synthesis of fi-
bronectin and collagen in several studies, there is a dis-
crepancy between the obtained results from protein and
gene expression [34]. We demonstrate that the combin-
ation of pirfenidone with rapamycin produces more effi-
cient results in the regulation of TGF−β-induced ECM
over-expression, and highlights the importance of find-
ing a new combinatory therapy for the treatment of pul-
monary fibrosis.
Another important finding is the clear inhibition of
TGF−β -induced myofibroblast transformation when fi-
broblasts are stimulated with pirfenidone and rapamycin,
although the main effect is likely due to the action of
pirfenidone. As shown in Fig. 4a, b, α-SMA was inhib-
ited when cells were treated with both agents in the ab-
sence or presence of TGF−β, indicating a decrease in
TGF−β -induced over-expression. Myofibroblasts are the
last cells recruited to repair tissue damage; however, un-
controlled accumulation of this type of cell halts the heal-
ing process, resulting in the fibrotic and dysfunctional
tissue. On the other hand, in agreement with other groups
[35, 36], we found that pirfenidone and rapamycin failed
to revert the EMT transition triggered by TGF−β in alveo-
lar epithelial cells, as shown the studies of E-cadherin
marker expression in A549 cells (Fig. 8). The discrepancy
in the results we obtained in epithelial cells could be due
a
b
Fig. 8 Pirfenidone and rapamycin treatment in the presence of TGF
−β has no effect on EMT pathway. A549 cells were incubated with
TGF−β (5 ng/ml), pirfenidone (1 mg/ml) and rapamycin (1 μg/ml) for
72 h. a E-cadherin protein expression measured by western blot in
A549 cells. Representative blots of one out of three separate experiments.
Expression of α-tubulin was used to normalize sample loading.
b E-cadherin transcript fold changes expressed as relative gene
expression (RGE) was analyzed by RT-PCR. Reported values are
the mean ± SEM of the transcript fold changes expressed as relative
gene expression (RGE) observed in three different experiments. Levels
of significance; * p < 0.05; ** p < 0.01. * indicates the comparison
between samples treated with TGF−β and all the other conditions:
TGF−β versus untreated samples (control); rapamycin and pirfenidone
(rapa/pirfe); and samples treated with TGF−β in combination
with rapamycin (TGF−β/rapa); pirfenidone (TGF−β/pirfe) or both
(TGF−β/rapa/pirfe). n.s statistically not significant
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to the use of A549 cell line. It has been reported that even
when these cells are standardized in in vitro models of
EMT, some factors must still be taken into account when
analyzing data obtained in this cell line [7]. We would
need to confirm our results in primary human type II al-
veolar epithelial cells from IPF patients to better under-
stand the potential effects of pirfenidone and rapamycin
on these cells.
The inhibition of cell migration by pirfenidone has
been reported by other groups [9, 33] whose results are
consistent with our findings in lung fibroblasts stimu-
lated with TGF−β and then treated with pirfenidone and
rapamycin. Furthermore, when cells were stimulated
with both drugs simultaneously, migration was inhibited
up to the last time point assayed (72 h). These results
support the role of both combined agents to avoid the
uncontrolled migration of fibroblasts in the injured tis-
sue. In vivo experimental studies would be required to
support the beneficial anti-fibrotic effect of pirfenidone
and rapamycin combination.
Conclusions
In summary, the present results open a new line of re-
search into the potential of pirfenidone and rapamycin
combination as a better anti-fibrotic approach and fu-
ture treatment strategies.
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